Global Liver Diseases Therapeutics Market Overview:
Global Liver Diseases Therapeutics Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2024 as the base year.
Global Liver Diseases Therapeutics Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Liver Diseases Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Liver Diseases Therapeutics Market:
The Liver Diseases Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Liver Diseases Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Liver Diseases Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Liver Diseases Therapeutics market has been segmented into:
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Application, Liver Diseases Therapeutics market has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Liver Diseases Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Liver Diseases Therapeutics market.
Top Key Players Covered in Liver Diseases Therapeutics market are:
Astellas Pharma Inc.
Bristol-Myers Squibb
Gilead Sciences
Glaxosmithkline Plc
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals
Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals
Inc.
Protagonist Therapeutics
Inc.
Dicerna Pharmaceuticals
Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma
Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Liver Diseases Therapeutics Market by Type
4.1 Liver Diseases Therapeutics Market Snapshot and Growth Engine
4.2 Liver Diseases Therapeutics Market Overview
4.3 Anti-Rejection Drugs/Immunosuppressant’s
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Anti-Rejection Drugs/Immunosuppressant’s: Geographic Segmentation Analysis
4.4 Chemotherapy Drugs
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Chemotherapy Drugs: Geographic Segmentation Analysis
4.5 Targeted therapy
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Targeted therapy: Geographic Segmentation Analysis
4.6 Vaccines
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Vaccines: Geographic Segmentation Analysis
4.7 Anti-Viral Drugs
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Anti-Viral Drugs: Geographic Segmentation Analysis
4.8 Immunoglobulin’s
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Immunoglobulin’s: Geographic Segmentation Analysis
4.9 Corticosteroids
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Corticosteroids: Geographic Segmentation Analysis
Chapter 5: Liver Diseases Therapeutics Market by Application
5.1 Liver Diseases Therapeutics Market Snapshot and Growth Engine
5.2 Liver Diseases Therapeutics Market Overview
5.3 Hospital Pharmacies
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
5.4 Retail Pharmacies
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Retail Pharmacies: Geographic Segmentation Analysis
5.5 Online Pharmacies
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Online Pharmacies: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Liver Diseases Therapeutics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTELLAS PHARMA INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BRISTOL-MYERS SQUIBB
6.4 GILEAD SCIENCES
6.5 GLAXOSMITHKLINE PLC
6.6 F. HOFFMANN-LA ROCHE LTD.
6.7 MERCK & CO. INC.
6.8 NOVARTIS AG
6.9 SANOFI S.A
6.10 PFIZER INC.
6.11 TAKEDA PHARMACEUTICAL
6.12 VALEANT PHARMACEUTICALS
6.13 WATSON PHARMACEUTICALS
6.14 INC.
6.15 THERATECHNOLOGIES INC.
6.16 ALNYLAM PHARMACEUTICALS
6.17 INC.
6.18 PROTAGONIST THERAPEUTICS
6.19 INC.
6.20 DICERNA PHARMACEUTICALS
6.21 INC.
6.22 ENDO INTERNATIONAL
6.23 PROVECTUS BIOPHARMACEUTICALS INC.
6.24 AND MAX BIOPHARMA
6.25 INC.
Chapter 7: Global Liver Diseases Therapeutics Market By Region
7.1 Overview
7.2. North America Liver Diseases Therapeutics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Anti-Rejection Drugs/Immunosuppressant’s
7.2.4.2 Chemotherapy Drugs
7.2.4.3 Targeted therapy
7.2.4.4 Vaccines
7.2.4.5 Anti-Viral Drugs
7.2.4.6 Immunoglobulin’s
7.2.4.7 Corticosteroids
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Hospital Pharmacies
7.2.5.2 Retail Pharmacies
7.2.5.3 Online Pharmacies
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Liver Diseases Therapeutics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Anti-Rejection Drugs/Immunosuppressant’s
7.3.4.2 Chemotherapy Drugs
7.3.4.3 Targeted therapy
7.3.4.4 Vaccines
7.3.4.5 Anti-Viral Drugs
7.3.4.6 Immunoglobulin’s
7.3.4.7 Corticosteroids
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Hospital Pharmacies
7.3.5.2 Retail Pharmacies
7.3.5.3 Online Pharmacies
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Liver Diseases Therapeutics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Anti-Rejection Drugs/Immunosuppressant’s
7.4.4.2 Chemotherapy Drugs
7.4.4.3 Targeted therapy
7.4.4.4 Vaccines
7.4.4.5 Anti-Viral Drugs
7.4.4.6 Immunoglobulin’s
7.4.4.7 Corticosteroids
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Hospital Pharmacies
7.4.5.2 Retail Pharmacies
7.4.5.3 Online Pharmacies
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Liver Diseases Therapeutics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Anti-Rejection Drugs/Immunosuppressant’s
7.5.4.2 Chemotherapy Drugs
7.5.4.3 Targeted therapy
7.5.4.4 Vaccines
7.5.4.5 Anti-Viral Drugs
7.5.4.6 Immunoglobulin’s
7.5.4.7 Corticosteroids
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Hospital Pharmacies
7.5.5.2 Retail Pharmacies
7.5.5.3 Online Pharmacies
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Liver Diseases Therapeutics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Anti-Rejection Drugs/Immunosuppressant’s
7.6.4.2 Chemotherapy Drugs
7.6.4.3 Targeted therapy
7.6.4.4 Vaccines
7.6.4.5 Anti-Viral Drugs
7.6.4.6 Immunoglobulin’s
7.6.4.7 Corticosteroids
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Hospital Pharmacies
7.6.5.2 Retail Pharmacies
7.6.5.3 Online Pharmacies
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Liver Diseases Therapeutics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Anti-Rejection Drugs/Immunosuppressant’s
7.7.4.2 Chemotherapy Drugs
7.7.4.3 Targeted therapy
7.7.4.4 Vaccines
7.7.4.5 Anti-Viral Drugs
7.7.4.6 Immunoglobulin’s
7.7.4.7 Corticosteroids
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Hospital Pharmacies
7.7.5.2 Retail Pharmacies
7.7.5.3 Online Pharmacies
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Liver Diseases Therapeutics Scope:
|
Report Data
|
Liver Diseases Therapeutics Market
|
|
Liver Diseases Therapeutics Market Size in 2025
|
USD XX million
|
|
Liver Diseases Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Liver Diseases Therapeutics Base Year
|
2024
|
|
Liver Diseases Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc..
|
|
Key Segments
|
By Type
Anti-Rejection Drugs/Immunosuppressant’s
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin’s
Corticosteroids
By Applications
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
|
